A5002532582- Hepatocellular Carcinoma Treatment and Prognosis
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Genetic factors in colorectal cancer
- Gastrointestinal Tumor Research and Treatment
- Cancer Genomics and Diagnostics
- Metastasis and carcinoma case studies
- Liver Disease Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Cancer Mechanisms and Therapy
- Hepatitis C virus research
- Colorectal Cancer Screening and Detection
- Gastrointestinal disorders and treatments
- Oral and Maxillofacial Pathology
- Intestinal and Peritoneal Adhesions
- Ferroptosis and cancer prognosis
- Cancer Cells and Metastasis
- Angiogenesis and VEGF in Cancer
- Lymphoma Diagnosis and Treatment
- Autophagy in Disease and Therapy
Tianjin Medical University Cancer Institute and Hospital
2015-2025
Fudan University
2025
Qingdao Agricultural University
2024
National Clinical Research
2014-2021
Tianjin Medical University
2007-2015
Showa University
2002-2007
Abstract Cancer of unknown primary (CUP) site poses diagnostic challenges due to its elusive nature. Many cases CUP manifest as pleural and peritoneal serous effusions. Leveraging cytological images from 57,220 at four tertiary hospitals, we developed a deep-learning method for tumor origin differentiation using histology (TORCH) that can identify malignancy predict in both hydrothorax ascites. We examined performance on three internal ( n = 12,799) two external 14,538) testing sets. In...
Abstract Colonoscopy is commonly used to screen for colorectal cancer (CRC). We develop a deep learning model called CRCNet optical diagnosis of CRC by training on 464,105 images from 12,179 patients and test its performance 2263 three independent datasets. At the patient-level, achieves an area under precision-recall curve (AUPRC) 0.882 (95% CI: 0.828–0.931), 0.874 (0.820–0.926) 0.867 (0.795–0.923). exceeds average endoscopists recall rate across two sets (91.3% versus 83.8%; two-sided...
Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and second leading cause of cancer-related deaths worldwide. Thus, methods for early diagnosis CRC are urgently needed. We aimed to identify potential long non-coding RNAs (lncRNAs) in circulatory exosomes that may serve as biomarkers detection early-stage CRC.Exosomes from plasma patients (n = 50) healthy individuals were isolated by ultracentrifugation, followed extraction total exosomal using TRIzol reagent....
// Jun Hu 1, * , Jian Li 2, Xin Yue 1 Jiacang Wang Jianzhong Liu Lin Sun 3 Dalu Kong Department of Colorectal Cancer Surgery, National Clinical Research Center for Cancer, Key Laboratory Prevention and Therapy Tianjin, Tianjin's Tianjin Medical University Institute Hospital, 300060, P.R. China 2 Lymphoma, State Experimental Hematology, Hematology Blood Disease Chinese Academy Sciences Peking Union College, 300020, Pathology, These authors have contributed equally to this work Correspondence...
Neoadjuvant chemoradiotherapy is the standard treatment for locally advanced rectal cancer, with modest benefits on tumor regression and survival. Since combined immune checkpoint inhibitors has been reported to have synergic effects. This study aims explore safety efficacy of long-course concurrent tislelizumab as a neoadjuvant regimen patients cancer. manuscript interim result prospective, multicenter, single-arm, phase II trial. Patients mid-to-low cancer clinical stages cT3-4a N0M0 or...
This study aimed to investigate the clinical utility of simultaneous measurement alphafetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) for hepatocellular carcinoma (HCC) diagnosis in Chinese patients predominantly caused by hepatitis B virus infection a multi-center case-controlled study. Subjects were 1,153 individuals from three major hospitals China, including 550 cases HCC group, 164 Malignant disease 182 Benign 85 Chronic liver 173 Normal group. Serum levels AFP DCP measured...
195 Background: In patients with advanced colorectal cancer (CRC), the recommended second-line treatment following first-line therapy oxaliplatin-based regimens is irinotecan-based therapy. Liposomal irinotecan, a novel formulation of traditional has demonstrated potential to enhance efficacy while minimizing toxicity. This study aims investigate and safety liposomal irinotecan in combination 5-FU/LV bevacizumab as option for metastatic CRC. Methods: multi-center, single-arm, prospective,...
Background Tumor development involves the critical role of programmed cell death (PCD), but correlation between colon adenocarcinoma (COAD) and PCD-related genes is not clear. Methods Subtyping analysis COAD was performed by consensus clustering based on The Cancer Genome Atlas (TCGA), with AC-ICAM queue from cBioportal database as a validation set. Immune infiltration samples evaluated using CIBERSORT Microenvironment Cell Populations (MCP)-counter algorithms. Patients’ immunotherapy...
Adjuvant interferon (IFN) therapy following curative treatment for hepatocellular carcinoma (HCC) has been extensively investigated; however, the clinical benefits with different hepatitis backgrounds remain unclear. Medline, Embase, PubMed and Cochrane Library databases were searched to identify randomized trials cohort studies that enrolled HCC patients who received surgery or ablation followed by IFN control subjects; required include data on early late recurrence mortality rates of HCC....
Abstract Background Long course radiotherapy plus neoadjuvant chemotherapy followed by resection (total mesorectal excision, TME) has accepted widespread recognized in the treatment of locally advanced rectal cancer (LARC). Tislelizumab, an anti-PD1 humanized IgG4 monoclonal antibody, been demonstrated with clinical activity and is approved for treating recurrent/refractory classical Hodgkin lymphoma advanced/metastatic urothelial carcinoma China. However, safety efficacy long (neoadjuvant...
Adjuvant therapy after resection of hepatocellular carcinoma (HCC) is limited. Here, we evaluated the effects postoperative sorafenib on recurrence and survival in HCC patients. Recurrence-free overall were analyzed as main endpoint, rate, mortality rate second endpoint. Furthermore, post-recurrence was also analyzed. Clinicopathological factors compared between control groups. Seventy-eight patients eligible for final data analysis (46 group; 32 group). Sorafenib did not significantly...
Abstract Aim The aim was to examine the effect of activated carbon nanoparticles ( ACN s) on lymph node retrieval in colorectal cancer CRC ) patients. Methods This prospective randomized study 80 subjects performed between March 2016 and December 2016. Eighty patients with were randomly divided into two groups, group a control group. subjected 1 ml injection subserosa around tumour before colectomy D3 lymphadenectomy. received same procedure without s. After surgery, nodes isolated, greatest...
Programmed death 1 (PD-1)-targeted therapy has benefited patients with microsatellite instability-high metastatic colorectal cancer (mCRC). However, the efficacy of PD-1-targeted is poor in microsatellite-stable (MSS) mCRC. Therefore, it imperative to explore additional co-inhibitory molecular signalling pathways improve immunotherapy MSS mCRC treatment. In present study, association between cyclin-dependent kinase 9 (CDK9) expression and survival CRC was analysed using RNA sequencing data...
Cyclin-dependent kinase 9 (CDK9) expression and autophagy in colorectal cancer (CRC) tissues has not been widely studied. CDK9, a key regulator of transcription, may influence the occurrence progression CRC. The autophagy-related genes
3599 Background: Tislelizumab (TIS), an anti-programmed cell death protein 1 (PD-1) antibody, demonstrated improved anti-tumor response and tolerable safety in patients (pts) with previously treated, locally advanced unresectable or metastatic microsatellite instability high/deficient mismatch repair (MSI-H/dMMR) solid tumors, including colorectal cancer (CRC; NCT03736889). Recent studies of other anti-PD-1 antibodies indicate potential clinical benefit neoadjuvant therapy pts resectable...
Many patients with hilar cholangiocarcinoma (HC) have a poor prognosis. Snail, transcription factor and E-cadherin repressor, is novel prognostic in many cancers. The aim of this study was to evaluate the relationship between snail protein expression significance HC. We examined HC tissues from 47 (22 males 25 females, mean age 61.2 years) using immunohistochemistry RT-PCR. Proliferation rate also evaluated same cases by MIB1 index. High, low negative recorded 18 (38%), 17 (36%), 12 (26%)...
e15599 Background: Long course radiotherapy plus neoadjuvant chemotherapy followed by resection (total mesorectal excision, TME) has accepted widespread recognized in the treatment of locally advanced rectal cancer (LARC). Tislelizumab, an anti-PD1 humanized IgG4 monoclonal antibody, been demonstrated with clinical activity and is approved for treating recurrent/refractory classical Hodgkin lymphoma advanced/metastatic urothelial carcinoma China. (neoadjuvant chemoradiotherapy, NCRT)...
The length of proximal margin for gastrectomy remains controversial. and its relationships with clinicopathological variables overall survival 922 gastric cancers were retrospectively analyzed. Proximal was divided into four groups (0–2.0, 2.1–4.0, 4.1–6.0, >6.0 cm). It indicated that the improved increase margin. 2.1–4.0 cm associated a better solitary-type (T1 T2 stages, N0 stage, tumor–node–metastasis stages I II, tumor size <5 cm, histological G1 G2, Bormann type II). Futhermore, 4.1–6.0...